GT
EVH icon

Glenmede Trust’s Evolent Health EVH Stock Holding History

Glenmede Trust’s Portfolio EVH Stock Details EVH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,150,414
Closed -$4.6M – 1500
2025
Q4 		$4.6M Buy
+1,150,414
New +$6.4M 0.02% 449
2025
Q1 		$10.5M Buy
1,109,427
+605,831
+120% +$6.12M 0.06% 346
2024
Q4 		$5.67M Sell
503,596
-227
-0% -$3.99K 0.03% 409
2024
Q3 		$14.2M Sell
503,823
-112
-0% -$2.89K 0.07% 292
2024
Q2 		$9.64M Buy
503,935
+2,945
+0.6% +$75.2K 0.05% 355
2024
Q1 		$16.4M Buy
500,990
+34,066
+7% +$1.09M 0.08% 254
2023
Q4 		$15.4M Sell
466,924
-11,888
-2% -$336K 0.08% 253
2023
Q3 		$13M Sell
478,812
-5,388
-1% -$150K 0.07% 283
2023
Q2 		$15.7M Buy
484,200
+952
+0.2% +$30.8K 0.09% 239
2023
Q1 		$15.7M Buy
483,248
+5,291
+1% +$167K 0.09% 240
2022
Q4 		$13.4M Sell
477,957
-62,674
-12% -$1.8M 0.08% 280
2022
Q3 		$19.4M Sell
540,631
-287,829
-35% -$10.1M 0.12% 187
2022
Q2 		$25.4M Sell
828,460
-90,650
-10% -$2.64M 0.15% 158
2022
Q1 		$29.7M Sell
919,110
-9,295
-1% -$243K 0.15% 161
2021
Q4 		$25.7M Sell
928,405
-7,258
-0.8% -$208K 0.12% 195
2021
Q3 		$29M Sell
935,663
-11,500
-1% -$276K 0.15% 162
2021
Q2 		$20M Sell
947,163
-2,241
-0.2% -$44.9K 0.1% 227
2021
Q1 		$19.2M Sell
949,404
-249,844
-21% -$4.75M 0.1% 224
2020
Q4 		$19.2M Sell
1,199,248
-91,833
-7% -$1.21M 0.11% 229
2020
Q3 		$16M Sell
1,291,081
-203,708
-14% -$2.4M 0.1% 238
2020
Q2 		$10.6M Sell
1,494,789
-802,223
-35% -$5.37M 0.07% 304
2020
Q1 		$20.8M Hold
2,297,012
– – 0.09% 272
2019
Q4 		$20.8M Sell
2,297,012
-270,222
-11% -$2.2M 0.09% 272
2019
Q3 		$18.5K Sell
2,567,234
-198,167
-7% -$1.42M 0.08% 282
2019
Q2 		$22K Buy
2,765,401
+2,765,281
+2,304,401% +$32.7M 0.1% 284
2019
Q1 		$1 Sell
120
-424
-78% -$6.71K ﹤0.01% 2922
2018
Q4 		$10 Buy
+544
New +$12.6K ﹤0.01% 2269

Other funds holding EVH

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RF
Rubicon Founders Nashville, Tennessee $138M AUM 61.96% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Glenmede Trust's EVH Position: Q1 2026 in Review

Glenmede Trust sold out of Evolent Health (EVH) in Q1 2026, closing a stake of 1,150,414 shares — an estimated $4.6M sold.

Glenmede Trust first reported a position in EVH in Q4 2018 and held it in 27 quarters. The position peaked at $29.7M in Q1 2022. 191 funds tracked by Wall St. Rank hold EVH as of Q1 2026.

  • Glenmede Trust reported no remaining Evolent Health position as of Q1 2026 after selling out during the quarter.
  • Glenmede Trust sold 1,150,414 Evolent Health shares in Q1 2026, an estimated $4.6M.
  • Glenmede Trust first reported a position in Evolent Health in Q4 2018 and held it in 27 quarters.
  • Glenmede Trust's Evolent Health position peaked at $29.7M in Q1 2022.
  • 191 funds tracked by Wall St. Rank held Evolent Health as of Q1 2026.

Based on Glenmede Trust's 13F filing for Q1 2026, filed 26 May 2026.